Medtronic has posted top- and bottom-line growth in its first fiscal quarter in spite of continued weakness in its cardiac rhythm disease management (CRDM) and spinal businesses.
The company's total revenue for Q1 increased 2% to $4.01bn, above the $3.94bn predicted by Morgan Stanley analyst David Lewis....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?